Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation

Overview

Journal J Lipids

Publisher Wiley

Date 2011 Jul 21

PMID 21773052

Citations 96

Authors

Klementina Fon Tacer

Damjana Rozman

Affiliations

Soon will be listed here.

Abstract

Obesity with associated comorbidities is currently a worldwide epidemic and among the most challenging health conditions in the 21st century. A major metabolic consequence of obesity is insulin resistance which underlies the pathogenesis of the metabolic syndrome. Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of obesity and metabolic syndrome. It comprises a disease spectrum ranging from simple steatosis (fatty liver), through nonalcoholic steatohepatitis (NASH) to fibrosis, and ultimately liver cirrhosis. Abnormality in lipid and lipoprotein metabolism accompanied by chronic inflammation is the central pathway for the development of metabolic syndrome-related diseases, such as atherosclerosis, cardiovascular disease (CVD), and NAFLD. This paper focuses on pathogenic aspect of lipid and lipoprotein metabolism in NAFLD and the relevant mouse models of this complex multifactorial disease.

Citing Articles

Association between the NHHR and hepatic steatosis and liver fibrosis: a population-based study.

Yang X, Yan H, Guo R, Chen Y Sci Rep. 2025; 15(1):8462.

PMID: 40069258 PMC: 11897350. DOI: 10.1038/s41598-025-90818-2.

Impact of binge drinking on alcoholic liver disease.

Kang J, Park S, Khanam M, Park S, Shin S, Seo W Arch Pharm Res. 2025; .

PMID: 40035998 DOI: 10.1007/s12272-025-01537-1.

Novel non-HDLc/HDLc ratio for predicting MASLD: a cross-sectional study in a Chinese health screening population.

Hong Y, Chen X, Yuan H, Huang Z, Tao S, Xie F BMC Gastroenterol. 2024; 24(1):439.

PMID: 39609681 PMC: 11603918. DOI: 10.1186/s12876-024-03525-z.

Exposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat.

Hughes J, Amin N, Wojciechowski J, Vourvahis M CPT Pharmacometrics Syst Pharmacol. 2024; 14(2):317-330.

PMID: 39564924 PMC: 11812935. DOI: 10.1002/psp4.13275.

Evaluating the Effects of Perinatal Exposures to BPSIP on Hepatic Cholesterol Metabolism in Female and Male Offspring ICR Mice.

Wang Q, Gao S, Chen B, Zhao J, Li W, Wu L Environ Health Perspect. 2024; 132(9):97011.

PMID: 39298647 PMC: 11412574. DOI: 10.1289/EHP14643.

References

Deng X, Chen L, Li N . The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int. 2007; 27(5):708-15. DOI: 10.1111/j.1478-3231.2007.01497.x. View

Iimuro Y, Gallucci R, Luster M, Kono H, Thurman R . Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology. 1997; 26(6):1530-7. DOI: 10.1002/hep.510260621. View

Moreau A, Teruel C, Beylot M, Albalea V, Tamasi V, Umbdenstock T . A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology. 2009; 49(6):2068-79. DOI: 10.1002/hep.22907. View

Goldberg A, Sapre A, Liu J, Capece R, Mitchel Y . Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004; 79(5):620-9. DOI: 10.4065/79.5.620. View

Horvat S, Bunger L, Falconer V, MacKay P, Law A, Bulfield G . Mapping of obesity QTLs in a cross between mouse lines divergently selected on fat content. Mamm Genome. 1999; 11(1):2-7. DOI: 10.1007/s003350010002. View

Verges B . New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab. 2005; 31(5):429-39. DOI: 10.1016/s1262-3636(07)70213-6. View

Yamashita H, Takenoshita M, Sakurai M, Bruick R, Henzel W, Shillinglaw W . A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci U S A. 2001; 98(16):9116-21. PMC: 55382. DOI: 10.1073/pnas.161284298. View

Yahagi N, Shimano H, Hasty A, Matsuzaka T, Ide T, Yoshikawa T . Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem. 2002; 277(22):19353-7. DOI: 10.1074/jbc.M201584200. View

Rector R, Thyfault J, Wei Y, Ibdah J . Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol. 2008; 14(2):185-92. PMC: 2675112. DOI: 10.3748/wjg.14.185. View

10.

McGarry J, Mannaerts G, Foster D . A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Invest. 1977; 60(1):265-70. PMC: 372365. DOI: 10.1172/JCI108764. View

11.

Cohen P, Miyazaki M, Socci N, Hagge-Greenberg A, Liedtke W, Soukas A . Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science. 2002; 297(5579):240-3. DOI: 10.1126/science.1071527. View

12.

Bunger L, Forsting J, McDonald K, Horvat S, Duncan J, Hochscheid S . Long-term divergent selection on fatness in mice indicates a regulation system independent of leptin production and reception. FASEB J. 2002; 17(1):85-7. DOI: 10.1096/fj.02-0111fje. View

13.

Larter C, Yeh M, Van Rooyen D, Teoh N, Brooling J, Hou J . Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J Gastroenterol Hepatol. 2009; 24(10):1658-68. DOI: 10.1111/j.1440-1746.2009.05996.x. View

14.

Olofsson S, Stillemark-Billton P, Asp L . Intracellular assembly of VLDL: two major steps in separate cell compartments. Trends Cardiovasc Med. 2001; 10(8):338-45. DOI: 10.1016/s1050-1738(01)00071-8. View

15.

Kotronen A, Yki-Jarvinen H . Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2007; 28(1):27-38. DOI: 10.1161/ATVBAHA.107.147538. View

16.

Foufelle F, Ferre P . New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J. 2002; 366(Pt 2):377-91. PMC: 1222807. DOI: 10.1042/BJ20020430. View

17.

Ntambi J, Miyazaki M, Stoehr J, Lan H, Kendziorski C, Yandell B . Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci U S A. 2002; 99(17):11482-6. PMC: 123282. DOI: 10.1073/pnas.132384699. View

18.

Chang X, Yan H, Fei J, Jiang M, Zhu H, Lu D . Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res. 2010; 51(9):2504-15. PMC: 2918435. DOI: 10.1194/jlr.M001958. View

19.

Jiang G, Li Z, Liu F, Ellsworth K, Dallas-Yang Q, Wu M . Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. J Clin Invest. 2005; 115(4):1030-8. PMC: 1062893. DOI: 10.1172/JCI23962. View

20.

Araya J, Rodrigo R, Pettinelli P, Araya A, Poniachik J, Videla L . Decreased liver fatty acid delta-6 and delta-5 desaturase activity in obese patients. Obesity (Silver Spring). 2009; 18(7):1460-3. DOI: 10.1038/oby.2009.379. View